Literature DB >> 35320389

Diagnostic value of colposcopy in patients with cytology-negative and HR-HPV-positive cervical lesions.

Yang Liu1, Jing Liao2, Xiaojia Yi3, Zhengmei Pan1, Jing Pan2, Chunyi Sun2, Honglin Zhou2, Yushi Meng4.   

Abstract

PURPOSE: High-risk human papillomavirus (HR-HPV)-positive but cytology-negative cervical cancer screening results are not uncommon. This study aimed to investigate colposcopy's accuracy and diagnostic value in patients with cytology-negative HR-HPV-positive screening results.
METHODS: This retrospective study included patients with HR-HPV-positive cytology-negative screening results who underwent electronic colposcopy with acetic acid and multi-point cervical biopsy, HPV typing (24 HPV subtypes), and quantitative HPV detection.
RESULTS: Among 229 patients, 130 had chronic cervicitis, and 99 had cervical lesions (CIN1, n = 37; CIN2/3, n = 55; invasive carcinoma, n = 7). Using colposcopy as a reference, the cervical cytology false-negative rate was 43.2% (99/229). Colposcopy was more accurate in patients with HR-HPV16/18 or high viral loads. Multivariable analyses showed HPV viral load and childbearing history were the independent factors affecting the accuracy of colposcopy (P < 0.05).
CONCLUSION: Colposcopy in HR-HPV-positive cytology-negative patients has a moderate diagnostic accuracy. The type of cervical transformation zone and HPV viral load are independent factors affecting the accuracy of colposcopy-based diagnosis.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Cervical intraepithelial neoplasia; Colposcopy; Human papillomavirus 16; Papillomavirus infections; Uterine cervical neoplasms

Mesh:

Year:  2022        PMID: 35320389     DOI: 10.1007/s00404-022-06415-5

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.493


  27 in total

Review 1.  The distribution and prevalence of human papillomavirus in women in mainland China.

Authors:  Kemin Li; Qingli Li; Liang Song; Danqing Wang; Rutie Yin
Journal:  Cancer       Date:  2019-02-12       Impact factor: 6.860

2.  Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive.

Authors:  Hormuzd A Katki; Mark Schiffman; Philip E Castle; Barbara Fetterman; Nancy E Poitras; Thomas Lorey; Li C Cheung; Tina Raine-Bennett; Julia C Gage; Walter K Kinney
Journal:  J Low Genit Tract Dis       Date:  2013-04       Impact factor: 1.925

Review 3.  Molecular tests potentially improving HPV screening and genotyping for cervical cancer prevention.

Authors:  Ana Gradíssimo; Robert D Burk
Journal:  Expert Rev Mol Diagn       Date:  2017-02-20       Impact factor: 5.225

4.  [Comparative study of HR HPV E6/E7 mRNA and HR-HPV DNA in cervical cancer screening].

Authors:  Xuye Zhao; Yong Cui; Shufang Jiang; Yuanguang Meng; Aijun Liu; Linping Wei; Tongyu Liu; Haiqiong Han; Xiaosu Liu; Fuhong Liu; Yali Li
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2014-11-25

5.  Cancer Statistics, 2021.

Authors:  Rebecca L Siegel; Kimberly D Miller; Hannah E Fuchs; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2021-01-12       Impact factor: 508.702

6.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

7.  Human papillomavirus infection rate, distribution characteristics, and risk of age in pre- and postmenopausal women.

Authors:  Yan Shen; Jing Xia; Huihui Li; Yang Xu; Sanping Xu
Journal:  BMC Womens Health       Date:  2021-02-25       Impact factor: 2.809

8.  Prevalence and Genotype Distribution of Human Papillomavirus Among Healthy Females in Beijing, China, 2016-2019.

Authors:  Hao Yu; Jie Yi; Ya-Ling Dou; Yu Chen; Ling-Jun Kong; Jie Wu
Journal:  Infect Drug Resist       Date:  2021-10-10       Impact factor: 4.003

9.  MicroRNA-218 regulates the chemo-sensitivity of cervical cancer cells through targeting survivin.

Authors:  Minmin Yu; Baozhen Xu; Hui Yang; Songlin Xue; Rong Zhang; Hongmei Zhang; Xiaoyan Ying; Zhiqin Dai
Journal:  Cancer Manag Res       Date:  2019-07-12       Impact factor: 3.989

10.  High risk HPV infection prevalence and associated cofactors: a population-based study in female ISSSTE beneficiaries attending the HPV screening and early detection of cervical cancer program.

Authors:  K Torres-Poveda; I Ruiz-Fraga; V Madrid-Marina; M Chavez; V Richardson
Journal:  BMC Cancer       Date:  2019-12-10       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.